BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 29438157)

  • 1. Effects of Varenicline Alone and in Combination With Low-dose Naltrexone on Alcohol-primed Smoking in Heavy-drinking Tobacco Users: A Preliminary Laboratory Study.
    Roberts W; Shi JM; Tetrault JM; McKee SA
    J Addict Med; 2018; 12(3):227-233. PubMed ID: 29438157
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Varenicline, low dose naltrexone, and their combination for heavy-drinking smokers: human laboratory findings.
    Ray LA; Courtney KE; Ghahremani DG; Miotto K; Brody A; London ED
    Psychopharmacology (Berl); 2014 Oct; 231(19):3843-53. PubMed ID: 24733235
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Varenicline, naltrexone, and their combination for heavy-drinking smokers: preliminary neuroimaging findings.
    Ray LA; Courtney KE; Ghahremani DG; Miotto K; Brody A; London ED
    Am J Drug Alcohol Abuse; 2015 Jan; 41(1):35-44. PubMed ID: 24949564
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Distress Tolerance and Craving for Cigarettes Among Heavy Drinking Smokers.
    Lim AC; Roche DJO; Ray LA
    J Stud Alcohol Drugs; 2018 Nov; 79(6):918-928. PubMed ID: 30573023
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of varenicline on alcohol self-administration and craving in drinkers with depressive symptoms.
    Roberts W; Verplaetse TL; Moore K; Oberleitner L; Picciotto MR; McKee SA
    J Psychopharmacol; 2017 Jul; 31(7):906-914. PubMed ID: 28351203
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combining Varenicline (Chantix) with Naltrexone Decreases Alcohol Drinking More Effectively Than Does Either Drug Alone in a Rodent Model of Alcoholism.
    Froehlich JC; Fischer SM; Dilley JE; Nicholson ER; Smith TN; Filosa NJ; Rademacher LC
    Alcohol Clin Exp Res; 2016 Sep; 40(9):1961-70. PubMed ID: 27469281
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Naltrexone and alcohol effects on craving for cigarettes in heavy drinking smokers.
    Green R; Bujarski S; Lim AC; Venegas A; Ray LA
    Exp Clin Psychopharmacol; 2019 Jun; 27(3):257-264. PubMed ID: 30628813
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination treatment with varenicline and naltrexone reduces World Health Organization risk drinking levels.
    Nieto SJ; Enders CK; Witkiewitz K; O'Malley SS; Ray LA
    Alcohol Clin Exp Res; 2022 Dec; 46(12):2258-2266. PubMed ID: 36515648
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined varenicline and naltrexone treatment reduces smoking topography intensity in heavy-drinking smokers.
    Roche DJ; Bujarski S; Hartwell E; Green R; Ray LA
    Pharmacol Biochem Behav; 2015 Jul; 134():92-8. PubMed ID: 25933795
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of varenicline on alcohol cue reactivity in heavy drinkers.
    Roberts W; Harrison ELR; McKee SA
    Psychopharmacology (Berl); 2017 Sep; 234(18):2737-2745. PubMed ID: 28600734
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A preliminary investigation of varenicline for heavy drinking smokers.
    Fucito LM; Toll BA; Wu R; Romano DM; Tek E; O'Malley SS
    Psychopharmacology (Berl); 2011 Jun; 215(4):655-63. PubMed ID: 21221531
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Varenicline reduces alcohol self-administration in heavy-drinking smokers.
    McKee SA; Harrison EL; O'Malley SS; Krishnan-Sarin S; Shi J; Tetrault JM; Picciotto MR; Petrakis IL; Estevez N; Balchunas E
    Biol Psychiatry; 2009 Jul; 66(2):185-90. PubMed ID: 19249750
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of varenicline on cognitive performance in heavy drinkers: Dose-response effects and associations with drinking outcomes.
    Roberts W; McKee SA
    Exp Clin Psychopharmacol; 2018 Feb; 26(1):49-57. PubMed ID: 29389170
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of Combining Varenicline and Naltrexone for Smoking Cessation and Drinking Reduction: A Randomized Clinical Trial.
    Ray LA; Green R; Enders C; Leventhal AM; Grodin EN; Li G; Lim A; Hartwell E; Venegas A; Meredith L; Nieto SJ; Shoptaw S; Ho D; Miotto K
    Am J Psychiatry; 2021 Sep; 178(9):818-828. PubMed ID: 34080890
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antidepressants for smoking cessation.
    Hajizadeh A; Howes S; Theodoulou A; Klemperer E; Hartmann-Boyce J; Livingstone-Banks J; Lindson N
    Cochrane Database Syst Rev; 2023 May; 5(5):CD000031. PubMed ID: 37230961
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined varenicline and naltrexone attenuates alcohol cue-elicited activation in heavy drinking smokers.
    Grodin EN; Burnette EM; Green R; Lim AC; Miotto K; Ray LA
    Drug Alcohol Depend; 2021 Aug; 225():108825. PubMed ID: 34175784
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Double-Blind Randomized Placebo-Controlled Trial of Oral Naltrexone for Heavy-Drinking Smokers Seeking Smoking Cessation Treatment.
    Kahler CW; Cioe PA; Tzilos GK; Spillane NS; Leggio L; Ramsey SE; Brown RA; O'Malley SS
    Alcohol Clin Exp Res; 2017 Jun; 41(6):1201-1211. PubMed ID: 28401564
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of Nicotine Patch vs Varenicline vs Combination Nicotine Replacement Therapy on Smoking Cessation at 26 Weeks: A Randomized Clinical Trial.
    Baker TB; Piper ME; Stein JH; Smith SS; Bolt DM; Fraser DL; Fiore MC
    JAMA; 2016 Jan; 315(4):371-9. PubMed ID: 26813210
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of varenicline for smoking cessation in people living with HIV in France (ANRS 144 Inter-ACTIV): a randomised controlled phase 3 clinical trial.
    Mercié P; Arsandaux J; Katlama C; Ferret S; Beuscart A; Spadone C; Duvivier C; Reynes J; Wirth N; Moinot L; Bénard A; Zucman D; Duval X; Molina JM; Spire B; Fagard C; Chêne G;
    Lancet HIV; 2018 Mar; 5(3):e126-e135. PubMed ID: 29329763
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of Lowering the Dose of Varenicline on Alcohol Self-administration in Drinkers With Alcohol Use Disorders.
    Verplaetse TL; Pittman BP; Shi JM; Tetrault JM; Coppola S; McKee SA
    J Addict Med; 2016; 10(3):166-73. PubMed ID: 27159341
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.